论文部分内容阅读
2007年5月《新英格兰医学杂志》上发表了一篇荟萃分析文章,提示罗格列酮治疗2型糖尿病可能增加患者心脏病发作和死亡风险,引发了临床医师处方该药的疑虑。2009年6月5日-9日在美国新奥尔良举行的第69届美国糖尿病学会(ADA)科学年会上相继公布了2项罗格列酮的大型临床研究——RECORD及BARI 2D研究,2项研究从不同角度对罗格列酮的安全性及疗效进行了长期深入的观察,为罗格列酮的临床应用提供了充分可靠的循证医学证据。
A meta-analysis published in the New England Journal of Medicine in May 2007 suggested that rosiglitazone may increase the risk of heart attack and death in patients with type 2 diabetes, triggering concerns that clinicians prescribe the drug. Two major clinical studies of rosiglitazone, the RECORD and BARI 2D studies, were announced one after another at the 69th American Diabetes Society (ADA) Annual Scientific Conference in New Orleans, June 5-9, 2009, 2 Term study of the safety and efficacy of rosiglitazone from different angles for a long period of in-depth observation of the clinical application of rosiglitazone provided reliable evidence-based medical evidence.